Abstract. Background/Aim: Osteosarcoma is the most common type of bone cancer, but current therapeutic interventions remain largely insufficient. The development of new treatment strategies is needed, and moreover, optimal rodent models are necessary for testing the efficacy of new treatment modalities of osteosarcoma. Humanized mice carry human hematopoietic and immune systems, and are considered an ideal tool to study human diseases including cancer immunology. Herein, we performed a preliminary study toward developing an in vivo bioluminescent osteosarcoma model using humanized immunodeficient (NSG) mice.

Materials and Methods: To establish the xenograft and orthotopic mouse model, NSG mice engrafted with human CD34+ hematopoietic stem cells were injected with luciferase-expressing KHOS/NP cells at two different time points. Bioluminescence images were obtained to monitor in vivo tumor growth and metastasis. Influence of the degree of human cell engraftment on tumor growth and metastatic behavior was analyzed and compared between the two groups.

Results: KHOS/NP-luc cells injected in humanized NSG mice formed macroscopic tumors. The percentage of human CD45+ cells in these models was similar, but the percentage of human CD45+CD3+ and their subset was higher in the late-injection group compared to that of the early-injection group. The rate of KHOS/NP tumor growth was higher in the early-injection group than in the late-injection group. In the present study, human hematopoietic cell engraftment was not influenced by KHOS/NP cell injection, but KHOS/NP osteosarcoma showed more aggressive behavior in the early-injection group than that in the late-injection group, forming larger tumor volumes and earlier metastases. Conclusion: The results indicated that tumor growth and progression in humanized NSG mice may have been influenced by higher levels of human cell engraftment, especially T cells. Although there exist some limitations to our study, our preliminary results can provide the basis for the development of a humanized osteosarcoma mouse model.

Osteosarcoma is the most common malignant bone tumor with a peak incidence occurring in adolescents. As the survival rate of patients with osteosarcoma has reached a plateau, the development of new treatment strategies based on its molecular characteristics are needed (1-3). As investigators search for novel agents, optimal in vitro or in vivo testing models are necessary. Animal models are widely used as preclinical platforms to test the efficacy of new treatment modalities. Due to the importance of bone and immune microenvironments in osteosarcoma, animal models recapitulating the human immune system are desirable in order to obtain more insight into the processes of osteosarcoma initiation, progression, and metastasis, as well as treatment sensitivity (4, 5). Super immunodeficient mice, such as NOD-scid IL2rgnull (NSG) mice, engraft human cells and tissues more efficiently than other models (6). Meanwhile, humanized mice carry human hematopoietic and immune systems and are considered an ideal tool to study hematopoiesis, infectious disease, and immunology (7-10).

Limited data exist on how to establish humanized mice bearing human tumors. Clearly, humanized NSG mice need specialized care and usually have a limited life span. In addition, the optimal time for tumor cell injection after humanization and the monitoring of tumor behavior in a less...
A

Busulfan pre-conditioning at 48 and 24 h prior

8th (early injection group) or 17th week (late injection group)

1X10^6 hCD34+ cells in retro orbital sinus (●)

Tumor size measurement & Bioluminescence imaging

12th (early injection group) or 21st week (late injection group)

KHOS/NP-luc cells 2 X 10^6 cells/100 µl in thigh (●)

Sacrifice and Analysis

3-4 wks old NSG

Con-NSG

Hu-NSG

Con-NSG

Xeno-Hu-NSG

B

|                | BM | SPL | BM | SPL |
|----------------|----|-----|----|-----|
| hCD34+ cells   |     |     |     |     |
| (%) of total live cells |     |     |     |     |

Early injection group

Late injection group

Con-NSG

Xeno-Hu-NSG

C

Day after tumor implantation

4  11  14  25  28  32

Early injection group

Late injection group

Figure 1. Continued
using human CD34+ cell transplantation (8 weeks and 17 weeks), expressing KHOS/NP cells at two different time points after influence tumor behavior. In the current study, we aimed to timing of tumor cell injection after humanization may engraftment in NSG mice following human CD34+ cell immune cells and tumor cells in NSG mice, we presume the observed a time-dependent increase of human cell Considering the interaction between engrafted human and metastatic behavior was then evaluated and compared for both a xenograft and an orthotopic model. Tumor growth for analysis of human cell reconstitution was analyzed at different times. The percentages are represented as the mean±SEM. (C, D) In vivo imaging and tumor measurements of Xeno-Hu-NSG mice. After KHOS/NP-luc cell injection, mice were imaged using a Bruker In-Vivo Xtreme system and the images quantified as photons/second using Bruker’s software. Tumor volumes were calculated on the indicated days. Details are described in Materials and Methods. Con-NSG: Normal NSG mice, Xeno-Hu-NSG: humanized osteosarcoma xenograft NSG mice, BM: bone marrow, SPL: spleen, *p<0.05.

Humanized NSG mice. NSG (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ) mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). For all experiments, mice were bred as a homozygous line and maintained under specific pathogen-free conditions at the Laboratory of Animal Research Center, Korea Institute of Radiological Medical Sciences (Seoul, Republic of Korea). Experiments were conducted according to the guidelines for ethical use of animals under an approved protocol (KIRAMS 2017-0046). Twelve 3-4-week-old female NSG mice were randomly divided into three groups (control, early-injection group, late-injection group) and conditioned with busulfan (Korea Otsuka Pharmaceutical, Seoul, Republic of Korea). Busulfan was dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich Corporation, St. Louis, MO, USA), diluted with 0.9% saline, and intraperitoneally injected into the NSG mice (25 mg/kg body weight, 500-625 μg per dose) 48 and 24 h prior to transplantation. To generate humanized NSG (Hu-NSG) mice, each mouse was intravenously transplanted via the retro-orbital sinus with 1x10^5 human CD34+ cells (hCD34+, Thermo Fisher Scientific, Inc.) in 100 μl phosphate-buffered saline (PBS). Enolofloxacin (0.27 mg/ml) was used as a prophylactic antibiotic in the drinking water of the mice to prevent urinary tract infections.

Materials and Methods

Osteosarcoma cells. The human osteosarcoma cell line KHOS/NP was purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA). The cells were maintained in Minimum Essential Medium α (MEM α; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (Thermo Fisher Scientific, Inc.), under 5% CO₂ conditions at 37°C.

Transfection with luciferase. The KHOS/NP cells were transfected with a luciferase expression vector (Promega, Madison, WI, USA) and selected under culture conditions including hygromycin B (Thermo Fisher Scientific, Inc.) according to the manufacturer’s instructions. Luciferase-expressing KHOS/NP osteosarcoma cells (KHOS/NP-luc cells) were tested for promoter activation using a luciferase assay (Thermo Fisher Scientific, Inc.) and a Bruker In-Vivo Xtreme imaging system (Bruker BioSpin Corp., Billerica, MA, USA).

invasive manner are matters of debate. We previously observed a time-dependent increase of human cell engraftment in NSG mice following human CD34+ cell transplantation with busulfan conditioning (11, 12). Considering the interaction between engrafted human immune cells and tumor cells in NSG mice, we presume the timing of tumor cell injection after humanization may influence tumor behavior. In the current study, we aimed to establish a humanized osteosarcoma model using NSG mice. The humanized NSG mice were injected with luciferase-expressing KHOS/NP cells at two different time points after human CD34+ cell transplantation (8 weeks and 17 weeks), for both a xenograft and an orthotopic model. Tumor growth and metastatic behavior was then evaluated and compared using in-vivo bioluminescence images.

Xenograft and orthotopic mice model. For the xenograft (Xeno-Hu-NSG) model (Figure 1A), 2x10^6 KHOS/NP-luc cells were injected subcutaneously into the thighs of Hu-NSG mice under 3% isoflurane-induced general anesthesia on the 8th or 17th week post hCD34+ cell transplantation. Tumor volumes were then measured with precision calipers every 3-4 days for 4 weeks. For the orthotopic (Ortho-Hu-NSG) model (Figure 2A), 1x10^5 KHOS/NP-luc cells were injected into knee joints of Hu-NSG mice under 3% isoflurane-induced general anesthesia on the 8th or 17th week post hCD34+ cell transplantation and monitored for 2-4 weeks based on physical conditions of the mice. The general health of the transplanted mice was monitored daily.

In vivo bioluminescence images. All the mice under 3% isoflurane anesthesia were intraperitoneally injected twice a week with 150 mg/kg D-luciferin (Thermo Fisher Scientific, Inc.), and then imaged using the Bruker In-Vivo Xtreme imaging system.

Analysis after KHOS/NP-luc cell injection. For analysis of human cell engraftment, the mice were sacrificed 2-4 weeks after KHOS/NP cell injection. Mononuclear cells were isolated from the bone marrow and spleens of the mice and single-cell suspensions were prepared using standard procedures. The cells were then stained with the following antibodies: hCD45-APC (Miltenyi
Biotec, Madrid, Spain), and hCD3-FITC, hCD19-PE, hCD4-PE, and hCD8-PE-Cy5 (BD Biosciences, San Jose, CA, USA). Flow cytometry was performed using a FACSCantoII Cell Analyzer (BD Biosciences) with ten thousand to one million events acquired per sample and then analyzed using FACSDiva and Flowjo software (BD Biosciences).

Statistical analysis. All statistical analyses were performed using GraphPad Prism 5.0 (GraphPad Software, Inc., San Diego, CA, USA). Quantitative variables are expressed as mean±standard deviation (SD) and differences between groups were considered to be statistically significant at a p-value <0.05.

Results

KHOS/NP-luc cells were tested after selection using hygromycin B resistance to confirm luciferase expression (data not shown). Hu-NSG mice were humanized as previously described and then injected with KHOS/NP-luc
cells at the 8th week (early-injection group) or 17th week (late-injection group) after transplantation with human CD34+ cells as Xeno-Hu-NSG and Ortho-Hu-NSG osteosarcoma models.

Mice of the humanized osteosarcoma xenograft model were sacrificed 4 weeks after KHOS/NP-luc cell injection and analyzed for human cell engraftment by flow cytometry (Figure 1B). The percentage of human CD45+ cells in bone marrow of Xeno-Hu-NSG mice were 80.2% in the early-injection group and 83.1% in the late-injection group, similar to that of the control Hu-NSG mice. The percentage of human CD45+ cells tended to be higher in spleen of Xeno-Hu-NSG mice in the late-injection group than that in the early-injection group (63.6% vs. 39.1%, p=0.2). Human CD45+CD19+ cells were detected in only the bone marrow and the engraftment rate was higher in the Xeno-Hu-NSG early-injection group compared to that of the late-injection group (0.18% vs. 0.04%, p=0.047). The percentage of human CD45+CD3+ cells in bone marrow tended to be higher in the late-injection group than the early-injection group (0.24% vs. 0.18%, p=0.27). However, human CD45+CD3+ in spleen was significantly higher in the late-injection group compared to that of the early-injection group (0.56% vs. 2.6%, p=0.02). When T-cell subsets were analyzed among the gated human CD3+ population, CD3+CD4+ cells were detected in only the late-injection group and found to be 66.45% of bone marrow and 31.8% of spleen. The percentages of CD3+CD8+ cells tended to be higher in the late-injection group compared to the early-injection group, being 9.78% vs. 0%, respectively, in bone marrow (p=0.14) and 26.55% vs. 18.05%, respectively, in spleen (p=0.22). KHOS/NP-luc cells injected in NSG mice formed macroscopic tumors, but luciferase-derived signals decreased in a time-dependent manner. The rate of KHOS/NP tumor growth was higher in the early-injection group than that in the late-injection group with a 2.3-fold larger tumor volume at the end of the experiment (Figure 1C and D).

Mice of the early-injection group of the humanized osteosarcoma orthotopic model were sacrificed on the 18th day post KHOS/NP-luc cell injection due to the deteriorating condition of the Ortho-Hu-NSG mice (following IACUC guidelines), while mice of the late-injection group were sacrificed on the 4th week post KHOS/NP-luc cells injection (Figure 2B). The engraftment rate of human CD45+ cells was higher in bone marrow of the late-injection group compared to that of the early-injection group (81.2% vs. 62.1%, respectively), as well as in the spleen (58.85% vs. 38.4%, respectively). Human CD45+CD19+ cells were detected only in the bone marrow and exhibited slightly higher engraftment rates in the late-injection group than that in the early-injection group (0.056% vs. 0.027%, p=0.24). The percentage of human CD45+CD3+ cells was slightly higher in the late-injection group than that of the early-injection group in bone marrow (0.49% vs. 0.01%, p=0.05) and in spleen (3.49% vs. 0.53%, p=0.07). Human T-cell subsets were detected in the bone marrow and spleen of only the late-injection group. In bone marrow, the percentages of CD3+CD4+ and CD3+CD8+ cells were 58.3% and 13.1%, respectively. In the spleen,
percentages of CD3+CD4+ and CD3+CD8+ cells were 53.4% and 18.48%, respectively. The luciferase signal decreased in a time-dependent manner in the Ortho-Hu-NSG mice. Mice of the early-injection group tended to develop metastasis earlier and demonstrated a faster rate of tumor growth (Figure 2C). For mice of the early-injection group, luciferase signals were detected in the knee on day 4 and in the lungs on day 11. For mice of the late-injection group, luciferase signals were detected on day 13 in the knee. Although luciferase signals were not detected in areas of the chest, autopsy revealed multiple metastatic nodules in lungs.

Discussion

Animal models are useful for testing the efficacy of new treatment modalities of human diseases. Various approaches have been attempted to overcome the genetic differences between humans and animals, including the use of humanized mice. In a previous study, we observed that NSG mice support high levels of engraftment following injection with human CD34+ cells. Herein, we performed a preliminary study to develop an in vivo bioluminescent osteosarcoma model in humanized NSG mice.

Human hematopoietic cell engraftment in the current study was not influenced by KHOS/NP cell injection. The fractions of human CD45+ cells in model mice were similar to those of the control Hu-NSG mice, irrespective of the KHOS/NP transplanted sites and time points analyzed. Although the same number of KHOS/NP cells were transplanted, KHOS/NP osteosarcoma showed a more aggressive behavior in the early-injection group than that in the late-injection group, forming larger tumor volume and earlier metastases. We presume the cause may have been the interaction between the KHOS/NP cells and human hematopoietic cells or immune cells that replaced the endogenous mouse hematopoietic system. Tumor growth and progression in NSG mice may have been influenced by the degree of human cell engraftment, especially T cells. In our previous work, both B-cell and T-cell engraftment increased in a time-dependent manner after human hematopoietic stem cell transplantation. We observed that B-cell engraftment rates were similar between early-injection and late-injection groups. However, the percentages of human T cells (both CD3+CD4+ and CD3+CD8+) were higher in mice of the late-injection group. T cells in the tumor microenvironment play an essential role in immune surveillance (13-15). High level of T-cell infiltration in tumors is associated with better prognosis and response in several types of cancer (16-19). In the current study, we did not analyze the T cells in the KHOS/NP tumors formed in the NSG mice. As NSG mice are constitutively lacking T cells, T cells in tumor microenvironment would derive from engrafted T cells. Number of T cells in the KHOS/NP tumor microenvironment might correlate with T cell engraftment. Accordingly, we surmise that there might have been more interaction between T cells and KHOS/NP tumor cells in the late injection group than in the early injection group, and inhibited KHOS/NP tumor progression.

According to the Jackson laboratory’s report, C57BL/6J mice of approximately 3 or 4 weeks of age corresponds to 12.5 years of age in humans. Accordingly, 8 weeks (early injection) and 17 weeks (late injection) would correspond to 20 and 30 years of age, respectively. Considering the chronologic factors, mice of the early-injection group would correspond to osteosarcoma of adolescents and those of the late-injection group would correspond to human adults. The clinical characteristics and prognosis of osteosarcoma in humans differ according to age, with worse prognosis for adults. In the current study, we observed the opposite finding, with KHOS/NP tumors in the early-injection group showing a more aggressive behavior.

Our study had several limitations due to its preliminary nature. For instance, the number of mice tested was small, which may have affected the ability to reach statistical significance for some of the end-points evaluated. We failed to observe lung metastasis in Ortho-Hu-NSG mice of the late-injection group using the Bruker In-Vivo Xtreme imaging due to decreasing luciferase expression in the KHOS/NP cells, which occurred in a time-dependent manner. Therefore, establishing a technique or condition for stable luciferase-expression in KHOS/NP cells is needed.

In conclusion, human hematopoietic cell engraftment was not influenced by KHOS/NP cell injection in the examined models. KHOS/NP osteosarcoma showed more aggressive behavior in the early-injection group than that in the late-injection group, forming larger tumor volume and earlier metastases. The results indicated that tumor growth and progression in the humanized NSG mice may have been influenced by higher levels of human cell engraftment, especially T cells. Taken together, our preliminary results provide a basis for the development of humanized osteosarcoma mice models. Further studies are necessary to establish more sophisticated immunodeficient mice with greater human T-cell engraftment, as well as develop more sensitive in vivo tumor imaging techniques.

Conflicts of Interest

The Authors declare that there are no conflicts of interest.

Authors’ Contributions

Yunmi Ko: Project administration, methodology, experiment, visualization, writing of original draft; Yeon Ho Jeong: methodology, validation, data curation; Jin-Hee Seo: Supporting in animal experiments; Jun Ah Lee: Supervision, conceptualization, data curation, writing review and editing.
Acknowledgements

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2017R1D1A1B03036574) and 2016 Research Grant from Kangwon National University (No. 520160190).

References

1 Wedekind MF, Wagner LM and Cripe TP: Immuno therapy for osteosarcoma: Where do we go from here? Pediatr Blood Cancer 65(9): e27227, 2018. PMID: 29923370. DOI: 10.1002/pbc.27227

2 Luetke A, Meyers PA, Lewis I and Juergens H: Osteosarcoma - where do we stand? A state of the art review. Cancer Treat Rev 40(4): 523-532, 2014. PMID: 24345772. DOI: 10.1016/j.ctrv.2013.11.006

3 Victor Garcia J: Humanized mice for HIV and AIDS research. Nat Rev Immunol 17(7): 357-365, 2017. PMID: 28132674. DOI: 10.1038/nri.2018.31

4 Koirala P, Roth ME, Gill J, Piperdi S, Chinai JM, Geller DS, Makarov E, Akhter SP, Gorantla S, Bonasera SJ, Gendelman HE and Poluektova LY: Influence of age, irradiation and humanization on NSG mouse phenotypes. Biol Open 4(10): 1243-1252, 2015. PMID: 26353862. DOI: 10.1242/bio.013201

5 Wedekind MF, Wagner LM and Cripe TP: Immunotherapy for osteosarcoma: challenges and opportunities. Front Immunol 7: 353, 2016. PMID: 27683579. DOI: 10.3389/fimmu.2016.00353

6 Rongvaux A, Willinger T, Martinek J, Strowig T, Gearty SV, Tichehmann LL, Saito Y, Marches F, Halene S, Palucka AK, Manz MG and Flavell RA: Development and function of human innate immune cells in a humanized mouse model. Nat Biotechnol 32(4): 364-372, 2014. PMID: 24633240. DOI: 10.1038/nbt.2858

7 Knibbe-Hollinger JS, Fields NR, Chaudoin TR, Epstein AA, Makarov E, Akhter SP, Boronat S, Bonasera SJ, Gendelman HE and Poluektova LY: Influence of age, irradiation and humanization on NSG mouse phenotypes. Biol Open 4(10): 1243-1252, 2015. PMID: 26353862. DOI: 10.1242/bio.013201

8 Rongvaux A, Willinger T, Martinek J, Strowig T, Gearty SV, Tichehmann LL, Saito Y, Marches F, Halene S, Palucka AK, Manz MG and Flavell RA: Development and function of human innate immune cells in a humanized mouse model. Nat Biotechnol 32(4): 364-372, 2014. PMID: 24633240. DOI: 10.1038/nbt.2858

9 Agarwal Y, Beauty C, Ho S, Thurlow L, Das A, Kelly S, Castronova I, Salunke R, Biradar S, Yeshi T, Richardson A and Bilyt M: Development of humanized mice for immune system investigation: progress, promise and challenges. Nat Rev Immunol 12(11): 786-798, 2012. PMID: 23059428. DOI: 10.1038/nri.3311

10 Ko Y, Jeong YH and Lee JA: Transplantation of human umbilical cord blood CD34+ cells into the liver of newborn NOD/SCID/IL-2Rγnull (NSG) mice after busulfan conditioning. Blood Res 52(4): 316-319, 2017. PMID: 29333410. DOI: 10.5045/br.2017.52.4.316

11 Kang YK, Ko Y, Choi A, Choi HJ, Seo JH, Lee M and Lee JA: Humanizing NOD/SCID/IL-2Rγnull (NSG) mice using busulfan and retro-orbital injection of umbilical cord blood-derived CD34+ cells. Blood Res 51(1): 31-36, 2016. PMID: 27104189. DOI: 10.5045/br.2016.51.1.31

12 Ashizawa T, Izuka A, Nonomura C, Kontou R, Maeda C, Miyata H, Sugino T, Mitsuya K, Hayashi N, Nakasu Y, Maruyama K, Yamaguchi K, Kato i, Ito M and Akiyama Y: Antitumor effect of programmed death-1 (PD-1) blockade in humanized the NOG-MHC double knockout mouse. Clin Cancer Res 23(1): 149-158, 2017. PMID: 27458246. DOI: 10.1158/1078-0432.CCR-16-0122

13 Morton CL and Houghton PJ: Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc 2(2): 247-250, 2007. PMID: 17406581. DOI: 10.1038/nprot.2007.25

14 Wang Z, Li B, Ren Y and Ye Z: T-cell-based immunotherapy for osteosarcoma: challenges and opportunities. Front Immunol 7: 353, 2016. PMID: 27683579. DOI: 10.3389/fimmu.2016.00353

Received March 11, 2021
Revised April 23, 2021
Accepted April 26, 2021